Side effects is acne, increased hair growth, voice changes, and increased sexual desire, estrogenic effects like fluid retention and breast enlargement, and liver damage. The drug is an agonist of the androgen receptor, the biological target of androgens like testosterone and dihydrotestosterone and has strong anabolic effects and moderate androgenic effects, has moderate estrogenic effects. It was developed in 1955. Metandienone used AAS among professional and amateur athletes, and remains the most common orally active AAS for non-medical use. Metandienone was formerly for the treatment of hypogonadism, but has since been discontinued and withdrawn in most countries.